secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2025-06-27T23:59:59+00:00
Accession:  0001437749-25-021445
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech receives Nasdaq deficiency notice; 180 days to regain $1.00 bid price
--------------------------------------------------------------------------------

- Received Nasdaq deficiency letter on June 27, 2025 for bid price below $1.00 for 30 consecutive days.
- Must close at $1.00 or more for 10 consecutive days by December 24, 2025 to regain compliance.
- Company may consider a reverse stock split to cure the deficiency.
- If not compliant by Dec 24, may be eligible for second 180-day period if meeting other standards.
- Failure to regain compliance may lead to delisting from Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925021445/0001437749-25-021445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925021445/mbrx20250627_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-021445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer